[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [RiskMitigation](https://github.com/mm80843/T3.5/tree/main/docs/RiskMitigation/index.md) >> Individual ID:PBN__RiskMitigation_2516 

# __Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.__

## Risks possibly mitigated by this Mitigation

* [Variation in protection against re-infections](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1914.md)

## Closest similar item

* [Evaluate efficacy differences based on symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1187.md)
* [Implement regular and widespread symptom monitoring and testing, both symptomatic and asymptomatic](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2039.md)
* [Promote awareness about asymptomatic transmission, encourage individuals to practice preventive measures regardless of symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2315.md)
* [Increase testing capacity to include testing of mild or asymptomatic individuals to obtain a more accurate assessment of the prevalence.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2563.md)
* [Conduct clinical trials to determine the efficacy of drug therapies, develop new therapeutics](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1597.md)
* [Identify missing information and develop logical relations linking drugs, coronaviruses, and conditions for drug efficacy.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1966.md)
* [Improve testing frequency and accuracy, conduct seroprevalence surveys.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2514.md)
* [Conduct more efficacy studies in clinical settings to evaluate the impact of these measures on TB transmission](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1863.md)
* [Meta-analyses should carefully evaluate the quality and reliability of included studies and exclude studies with flawed or fraudulent data.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_3034.md)
* [Strengthen surveillance systems to actively detect and treat asymptomatic and unreported cases](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2833.md)

